S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$23.76
-1.0%
$27.90
$22.01
$33.71
$4.02B0.551.91 million shs1.80 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$13.58
+1.2%
$15.72
$7.88
$16.88
$6.69B1.294.38 million shs3.81 million shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$29.94
-0.3%
$30.64
$25.77
$40.28
$4.06B0.641.87 million shs971,546 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+1.01%-8.15%-12.79%-13.51%-17.91%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-1.72%-9.02%-14.97%-9.33%+43.73%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
Perrigo Company plc stock logo
PRGO
Perrigo
+0.30%-4.72%+0.13%-8.33%-17.24%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alkermes plc stock logo
ALKS
Alkermes
4.2304 of 5 stars
3.31.00.04.21.92.52.5
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
3.3098 of 5 stars
2.34.00.00.32.63.31.3
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
4.9557 of 5 stars
3.53.04.23.52.43.32.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.50
Moderate Buy$35.2548.36% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.57
Moderate Buy$16.7123.13% Upside
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
3.00
Buy$40.6735.83% Upside

Current Analyst Ratings

Latest GBT, ALKS, PRGO, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Perrigo Company plc stock logo
PRGO
Perrigo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00
4/9/2024
Alkermes plc stock logo
ALKS
Alkermes
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$42.00 ➝ $50.00
4/8/2024
Perrigo Company plc stock logo
PRGO
Perrigo
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$35.00 ➝ $39.00
4/1/2024
Alkermes plc stock logo
ALKS
Alkermes
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$39.00
3/19/2024
Alkermes plc stock logo
ALKS
Alkermes
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$37.00
2/28/2024
Perrigo Company plc stock logo
PRGO
Perrigo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$48.00 ➝ $41.00
2/27/2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$12.50 ➝ $14.00
2/27/2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$16.00 ➝ $17.00
2/27/2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$18.00 ➝ $19.00
2/20/2024
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell$25.00
2/16/2024
Alkermes plc stock logo
ALKS
Alkermes
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$35.00 ➝ $39.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.66B2.42$2.27 per share10.47$7.21 per share3.30
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.42B1.52$2.29 per share5.93$12.63 per share1.07
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
Perrigo Company plc stock logo
PRGO
Perrigo
$4.66B0.87$5.26 per share5.69$35.19 per share0.85

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$355.76M$2.0711.4811.370.6621.39%16.10%9.15%5/1/2024 (Confirmed)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B-$2.50N/A13.051.43-27.87%6.44%2.91%5/8/2024 (Confirmed)
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$12.70M-$0.10N/A9.30N/A-0.27%7.34%3.24%5/14/2024 (Estimated)

Latest GBT, ALKS, PRGO, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.26N/A-$0.26N/AN/AN/A  
5/1/2024N/A
Alkermes plc stock logo
ALKS
Alkermes
$0.54N/A-$0.54N/AN/AN/A  
2/27/202412/31/2023
Perrigo Company plc stock logo
PRGO
Perrigo
$0.83$0.86+$0.03$1.96$1.17 billion$1.16 billion      
2/26/202412/31/2023
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.10$0.08-$0.02$0.45$1.00 billion$1.04 billion      
2/15/2024Q4 23
Alkermes plc stock logo
ALKS
Alkermes
$0.51$0.22-$0.29$0.02$362.78 million$377.50 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.103.67%+6.66%N/A 22 Years

Latest GBT, ALKS, PRGO, and ELAN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2024
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.27603.43%3/7/20243/8/20243/26/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.24
2.86
2.50
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.92
2.75
1.35
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17
Perrigo Company plc stock logo
PRGO
Perrigo
0.76
1.79
1.07

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/A
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.76%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
6.40%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.90%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,100169.18 million161.13 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,300492.97 million461.42 millionOptionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
9,140135.52 million134.57 millionOptionable

GBT, ALKS, PRGO, and ELAN Headlines

SourceHeadline
Perrigo (PRGO) Price Target Increased by 5.19% to 41.31Perrigo (PRGO) Price Target Increased by 5.19% to 41.31
msn.com - April 17 at 5:46 PM
Heres Why Perrigo Company PLC (PRGO) Stock Slumped in Q1Here's Why Perrigo Company PLC (PRGO) Stock Slumped in Q1
msn.com - April 15 at 1:31 PM
Here’s Why Perrigo Company PLC (PRGO) Stock Slumped in Q1Here’s Why Perrigo Company PLC (PRGO) Stock Slumped in Q1
finance.yahoo.com - April 15 at 8:30 AM
Perrigo (NYSE:PRGO) Rating Reiterated by Canaccord Genuity GroupPerrigo (NYSE:PRGO) Rating Reiterated by Canaccord Genuity Group
americanbankingnews.com - April 14 at 3:26 AM
Canaccord Genuity Group Reiterates "Buy" Rating for Perrigo (NYSE:PRGO)Canaccord Genuity Group Reiterates "Buy" Rating for Perrigo (NYSE:PRGO)
marketbeat.com - April 12 at 12:16 PM
The WNBA has partnered with Glossier and Skims—now it’s added Opill, the new over-the-counter birth controlThe WNBA has partnered with Glossier and Skims—now it’s added Opill, the new over-the-counter birth control
finance.yahoo.com - April 11 at 12:31 PM
Raymond James & Associates Purchases 74,782 Shares of Perrigo Company plc (NYSE:PRGO)Raymond James & Associates Purchases 74,782 Shares of Perrigo Company plc (NYSE:PRGO)
marketbeat.com - April 10 at 4:13 AM
Opill and WNBA Team Up for Groundbreaking PartnershipOpill and WNBA Team Up for Groundbreaking Partnership
finance.yahoo.com - April 9 at 2:56 PM
Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend GrowthUpcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth
seekingalpha.com - April 9 at 7:02 AM
Perrigo (NYSE:PRGO) PT Raised to $39.00Perrigo (NYSE:PRGO) PT Raised to $39.00
americanbankingnews.com - April 9 at 3:46 AM
Perrigo shares get price target boost on resilient salesPerrigo shares get price target boost on resilient sales
investing.com - April 8 at 1:02 PM
Ceredex Value Advisors LLC Lowers Stake in Perrigo Company plc (NYSE:PRGO)Ceredex Value Advisors LLC Lowers Stake in Perrigo Company plc (NYSE:PRGO)
marketbeat.com - April 8 at 8:28 AM
Perrigo (NYSE:PRGO) PT Raised to $39.00 at Piper SandlerPerrigo (NYSE:PRGO) PT Raised to $39.00 at Piper Sandler
marketbeat.com - April 8 at 8:19 AM
Perrigo Company plc: Recent pullback offers a buying opportunity.Perrigo Company plc: Recent pullback offers a buying opportunity.
finance.yahoo.com - April 4 at 8:05 PM
CVS Caremark to cover Perrigos birth control pill in US at zero cost for plan sponsorsCVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors
reuters.com - April 4 at 4:59 PM
Perrigo (NYSE:PRGO) Upgraded to "Buy" by StockNews.comPerrigo (NYSE:PRGO) Upgraded to "Buy" by StockNews.com
marketbeat.com - April 3 at 11:11 PM
DAVENPORT & Co LLC Trims Stock Position in Perrigo Company plc (NYSE:PRGO)DAVENPORT & Co LLC Trims Stock Position in Perrigo Company plc (NYSE:PRGO)
marketbeat.com - April 3 at 12:38 AM
Perrigo Company plc (NYSE:PRGO) Shares Sold by Copeland Capital Management LLCPerrigo Company plc (NYSE:PRGO) Shares Sold by Copeland Capital Management LLC
marketbeat.com - March 31 at 9:30 AM
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
zacks.com - March 28 at 12:36 PM
PRGO Aug 2024 47.500 callPRGO Aug 2024 47.500 call
finance.yahoo.com - March 20 at 7:29 PM
Perrigo launches Opill, first OTC birth control pill in U.S.Perrigo launches Opill, first OTC birth control pill in U.S.
msn.com - March 19 at 1:13 PM
Reckitt unsure how many cases have been filed over Enfamil: reportReckitt unsure how many cases have been filed over Enfamil: report
msn.com - March 18 at 10:05 PM
BEYOND LOCAL: Opill, the first over-the-counter birth control pill, will be on shelves soon − here are some key things to knowBEYOND LOCAL: Opill, the first over-the-counter birth control pill, will be on shelves soon − here are some key things to know
longmontleader.com - March 18 at 2:02 AM
Analysts Offer Predictions for Perrigo Company plcs Q2 2024 Earnings (NYSE:PRGO)Analysts Offer Predictions for Perrigo Company plc's Q2 2024 Earnings (NYSE:PRGO)
marketbeat.com - March 18 at 1:44 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Alkermes logo

Alkermes

NASDAQ:ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Elanco Animal Health logo

Elanco Animal Health

NYSE:ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Global Blood Therapeutics logo

Global Blood Therapeutics

NASDAQ:GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Perrigo logo

Perrigo

NYSE:PRGO
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.